HomeCompareIUGNF vs XYLD

IUGNF vs XYLD: Dividend Comparison 2026

IUGNF yields 1788.91% · XYLD yields 10.98%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IUGNF wins by $3531675981.98M in total portfolio value
10 years
IUGNF
IUGNF
● Live price
1788.91%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3531675982.01M
Annual income
$3,181,793,952,650,469.00
Full IUGNF calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
10.98%
Share price
$39.13
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$3,219.02
Full XYLD calculator →

Portfolio growth — IUGNF vs XYLD

📍 IUGNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIUGNFXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IUGNF + XYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IUGNF pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IUGNF
Annual income on $10K today (after 15% tax)
$152,057.25/yr
After 10yr DRIP, annual income (after tax)
$2,704,524,859,752,898.50/yr
XYLD
Annual income on $10K today (after 15% tax)
$933.63/yr
After 10yr DRIP, annual income (after tax)
$2,736.17/yr
At 15% tax rate, IUGNF beats the other by $2,704,524,859,750,162.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IUGNF + XYLD for your $10,000?

IUGNF: 50%XYLD: 50%
100% XYLD50/50100% IUGNF
Portfolio after 10yr
$1765837991.02M
Annual income
$1,590,896,976,326,844.00/yr
Blended yield
90.09%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IUGNF buys
0
XYLD buys
0
No recent congressional trades found for IUGNF or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIUGNFXYLD
Forward yield1788.91%10.98%
Annual dividend / share$2.00$4.30
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$3531675982.01M$25.3K
Annual income after 10y$3,181,793,952,650,469.00$3,219.02
Total dividends collected$3506616114.25M$19.6K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: IUGNF vs XYLD ($10,000, DRIP)

YearIUGNF PortfolioIUGNF Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$189,591$178,890.88$10,818$1,098.39+$178.8KIUGNF
2$3,372,589$3,169,726.93$11,738$1,222.51+$3.36MIUGNF
3$56,305,450$52,696,779.78$12,774$1,364.64+$56.29MIUGNF
4$882,465,426$822,218,594.62$13,944$1,527.86+$882.45MIUGNF
5$12,987,684,313$12,043,446,306.47$15,270$1,715.87+$12987.67MIUGNF
6$179,550,479,073$165,653,656,858.63$16,775$1,933.09+$179550.46MIUGNF
7$2,332,406,409,977$2,140,287,397,368.80$18,490$2,184.87+$2332406.39MIUGNF
8$28,479,672,886,997$25,983,998,028,321.59$20,450$2,477.63+$28479672.87MIUGNF
9$326,992,550,798,860$296,519,300,809,773.56$22,697$2,819.19+$326992550.78MIUGNF
10$3,531,675,982,005,250$3,181,793,952,650,469.00$25,280$3,219.02+$3531675981.98MIUGNF

IUGNF vs XYLD: Complete Analysis 2026

IUGNFStock

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Full IUGNF Calculator →

XYLDETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this IUGNF vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IUGNF vs SCHDIUGNF vs JEPIIUGNF vs OIUGNF vs KOIUGNF vs MAINIUGNF vs QYLDIUGNF vs JEPQIUGNF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.